The latest report by IMARC Group, titled “Cancer/Tumor Profiling Market Report by Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, and Others), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In-Situ Hybridization (ISH), Microarray, and Others), Technique (Genomics, Proteomics, Epigenetics, Metabolomics), Application (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, and Others), and Region 2024-2032”, offers a comprehensive analysis of the industry, which comprises insights on cancer/tumor profiling market share.
Cancer/Tumor Profiling Market Forecast
The global cancer/tumor profiling market size reached US$ 11.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.6 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032.
Factors Affecting the Growth of the Cancer/Tumor Profiling Industry:
- Rising Cancer Incidence:
The increasing number of cancer incidences is due to the growing geriatric population, lifestyle changes, and environmental factors. In addition, the increasing life expectancy and changes in dietary habits, the prevalence of risk factors associated with cancer, such as obesity and tobacco use, are contributing to the rising incidence of the disease. Also, environmental factors such as pollution and exposure to carcinogens are linked to increased cancer rates. Moreover, an increasing need for more effective and targeted treatment options led to the adoption of cancer tumor profiling that addresses this need by providing insights into the molecular characteristics of tumors. Also, cancer profiling helps identify specific molecular targets for therapy and predict patient responses to different treatment modalities by analyzing the genetic makeup of cancer cells. This personalized approach to cancer treatment enables healthcare providers to tailor therapies to individual patients, maximizing efficacy while minimizing potential side effects.
- Technological Advancements:
Technological advancements are transforming cancer profiling, making it more accessible, cost-effective, and accurate. For instance, next-generation sequencing (NGS), microarray-based techniques, and bioinformatics tools are instrumental in driving progress in this field. NGS technologies, enable the rapid and comprehensive analysis of cancer genomes, transcriptomes, and epigenomes, allowing for the identification of genetic mutations and alterations associated with cancer development and progression. Besides this, microarray-based techniques complement NGS by providing high-throughput analysis of gene expression patterns and DNA copy number variations in cancer samples. These techniques offer valuable insights into the molecular mechanisms underlying tumorigenesis and facilitate the discovery of biomarkers for early detection and prognosis. Besides this, bioinformatics tools and computational algorithms are essential in processing and interpreting large-scale genomic data generated by NGS and microarray experiments, enabling researchers to extract meaningful insights from complex datasets.
- Increasing Adoption in Clinical Practice:
Cancer tumor profiling is experiencing growing adoption in routine clinical practice, particularly in the field of oncology. Healthcare providers are recognizing the value of genomic testing in guiding treatment decisions and improving patient outcomes. Additionally, clinicians are gaining valuable insights into the molecular characteristics of tumors and tailor treatment regimens to individual patients, by integrating cancer profiling into standard care pathways. It also assists clinicians in selecting appropriate therapies based on the specific molecular alterations present in a patient's tumor. For instance, targeted therapies that inhibit specific oncogenic pathways can be prescribed to patients with actionable mutations identified through genomic testing.
For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/cancer-tumor-profiling-market/requestsample
Competitive Landscape:
The competitive landscape of the market has been studied in the report with detailed profiles of the key players operating in the market.
- Abbott Laboratories
- Becton Dickinson and Company
- Caris Life Sciences
- Exact Sciences Corporation
- Hoffmann-La Roche Ltd
- Hologic Inc.
- HTG Molecular Diagnostics Inc.
- Illumina Inc.
- Laboratory Corporation of America Holdings
- NeoGenomics Laboratories
- Qiagen N.V.
- Siemens AG
- Sysmex Corporation.
Cancer/Tumor Profiling Market Report Segmentation:
By Cancer Type:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma Cancer
- Others
Breast cancer represents the largest segment due to its prevalence and the growing demand for personalized treatment options tailored to this specific cancer type.
By Technology:
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- In-Situ Hybridization (ISH)
- Microarray
- Others
On the basis of technology, the market is classified into next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in-situ hybridization (ISH), microarray, and others.
By Technique:
- Genomics
- Proteomics
- Epigenetics
- Metabolomics
Genomics emerges as the largest segment in terms of technique, reflecting the increasing adoption of advanced genomic technologies for comprehensive tumor analysis and molecular profiling.
By Application:
- Personalized Medicine
- Diagnostics
- Biomarker Discovery
- Prognostics
- Others
On the basis of application, the market is segregated into personalized medicine, diagnostics, biomarker discovery, prognostics, and others.
Regional Insight:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America’s dominance in the cancer/tumor profiling market is attributed to robust healthcare infrastructure, significant R&D investments, and high awareness regarding early cancer detection and treatment modalities.
Global Cancer/Tumor Profiling Market Trends:
At present, the widespread adoption of precision medicine approaches including tailored treatments based on individual patient characteristics, such as genetic makeup and tumor profiles is influencing the market growth. It is essential in guiding precision medicine strategies by identifying actionable molecular targets and predicting responses to targeted therapies and immunotherapies. Moreover, artificial intelligence (AI) and machine learning (ML) algorithms are integrated into cancer tumor profiling platforms to enhance data analysis, interpretation, and predictive modeling. These technologies enable the extraction of actionable insights from large-scale genomic, proteomic, and clinical datasets, improving the accuracy and efficiency of cancer diagnosis, prognosis, and treatment planning.
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=5231&flag=C
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company's expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
